Performance of Lung MRI Combined to Synthetic CT in the Follow-up of Lung Nodules

Condition(s) studied

Investigational drug(s) / intervention(s)

multiparametric MRI: An MRI scan will be performed within 2 weeks of the discovery of a solid lung nodule ≥ 5mm on the screening scan. When a follow-up scan is indicated, an MRI will be repeated on the same day as the follow-up scan. The MRI sequences that will be performed are: SpiraleVibe UTE, T1map, T2 map and Diffusion. A synthetic scanner image will be generated from the UTE morphological MRI image using a generative artificial intelligence (GAN) model.

Study summary

Lung cancer screening trials using low-dose chest CT scans have shown a significant reduction of cancer related mortality in subjects at high risk of lung cancer. However, high rate of false positives and overdiagnosis have led to invasive methods, which are not without risks. Evaluation of lung nodules using lung MRI with ultra short echo time sequences (UTE) has been found comparable to chest CT scans. Moreover, MRI has the advantage of multiparametric characterization of lesions using different tissue contrasts. Following the recommendation of the French National Authority for Health (HAS) to evaluate new methods of lung cancer screening, this prospective single center pilot study is designed to evaluate the performance of multiparametric lung MRI combined to synthetic CT in the diagnosis of lung cancer in heavily smokers or ex-smokers professionally exposed to carcinogens

Eligibility

Primary outcome measure(s)

• Positivity threshold — Baseline, Month 3, Month 12
  Positivity threshold of the combined score to obtain a specificity of at least 90%, and diagnostic performance parameters associated with this threshold (sensitivity, positive and negative predictive values).

Trial sites (1)

More University Hospital, Bordeaux trials in France

Other trials for the same condition